FDA grants orphan drug status for Merck’s pembrolizumab in NEPC

FDA grants orphan drug status for Merck’s pembrolizumab in NEPC

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.